RxDoctor Payments Data

Ina Agrawal, MD

Internal Medicine · Richmond, INNPI 1427058544

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 96 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$305
  • Lilly USA, LLC$287
  • AbbVie$255
  • Novo Nordisk$182
  • GSK$174
  • AstraZeneca$157
  • plus $154 from 6 others

What the payments were for

  • Food & beverage$1,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,514 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$99,638
Medicare patients
103
Services billed
1,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide43$60,621
EliquisApixaban96$55,045
MyrbetriqMirabegron81$42,231
XifaxanRifaximin12$36,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$36,127
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr65$30,431
MounjaroTirzepatide20$29,998
JardianceEmpagliflozin28$23,247
OzempicSemaglutide18$17,329
LinzessLinaclotide17$17,225
FarxigaDapagliflozin Propanediol36$16,615
QuliptaAtogepant15$13,445
Combivent RespimatIpratropium/Albuterol Sulfate23$11,217
RybelsusSemaglutide12$11,055
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$9,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$287$90,61963 claims
GSKTrelegy Ellipta, Anoro Ellipta$174$66,558109 claims
PfizerEliquis$25$55,04596 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$305$42,04367 claims
AbbVieLinzess, Qulipta$255$30,66932 claims
Novo NordiskOzempic, Rybelsus$182$28,38330 claims
AstraZenecaFarxiga$157$16,61536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →